Andra AP fonden Has $30.58 Million Stock Position in Medtronic PLC $MDT

Andra AP fonden lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 412.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 321,129 shares of the medical technology company’s stock after purchasing an additional 258,500 shares during the period. Andra AP fonden’s holdings in Medtronic were worth $30,584,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in MDT. Riverbend Wealth Management LLC lifted its stake in Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after acquiring an additional 107 shares during the last quarter. Holistic Financial Partners raised its holdings in shares of Medtronic by 3.0% in the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock valued at $352,000 after purchasing an additional 109 shares during the period. Wynn Capital LLC lifted its stake in Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after purchasing an additional 110 shares during the last quarter. Meridian Investment Counsel Inc. grew its holdings in Medtronic by 0.4% during the third quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after purchasing an additional 110 shares during the period. Finally, Saxony Capital Management LLC grew its holdings in Medtronic by 3.8% during the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock worth $290,000 after purchasing an additional 112 shares during the period. 82.06% of the stock is owned by institutional investors.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic plans to spin off its Diabetes segment via an IPO of MiniMed Group, a move that could unlock value by creating a focused, standalone diabetes business and give investors clearer exposure to high-growth diabetes assets. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Positive Sentiment: Medtronic’s MiniMed Group is pursuing a U.S. IPO (target ~ $784m), signaling management is executing a portfolio-shaping strategy and potentially accelerating value realization for MDT shareholders. Medtronic’s diabetes business MiniMed looks for $784m in US IPO
• Positive Sentiment: Commercial rollout: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in EMEA — a product that integrates insulin-pen data and continuous sensor data into a single app, expanding commercial reach in diabetes care. This supports recurring-revenue potential in a growth segment. Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
• Positive Sentiment: Product/clinical beat: Medtronic reported positive findings for its Altaviva tibial neuromodulation therapy for urinary incontinence — a clinical win that can support future commercial adoption in a meaningful urology market. Medtronic reports positive findings for Altaviva tibial neuromod for urinary incontinence
• Neutral Sentiment: Macro/relative performance: Analysts note MDT has underperformed the S&P 500 over the past year, though Wall Street remains moderately constructive — a reminder that valuation and index-relative dynamics could cap upside even as company-specific news is positive. Is Medtronic Stock Underperforming the S&P 500?
• Negative Sentiment: Insider sale: EVP & President Harry “Skip” Kiil sold 52,524 shares (transaction disclosed Feb. 19) for roughly $5.13M at an average price ~ $97.71, reducing his stake by ~61.6%. Large insider dispositions can weigh on sentiment even if they are routine or for diversification/liquidity reasons. Top Medtronic Executive Unloads a Major Chunk of Stock in High-Value Insider Deal

Analyst Upgrades and Downgrades

Several analysts have issued reports on MDT shares. TD Cowen restated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Jefferies Financial Group reiterated a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Sanford C. Bernstein increased their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Finally, William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $110.84.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.26% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $96.97 on Friday. The business has a fifty day moving average price of $98.95 and a two-hundred day moving average price of $96.83. The stock has a market capitalization of $124.50 billion, a PE ratio of 27.01, a P/E/G ratio of 2.43 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.80. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s payout ratio is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).